ResearchPod Summary
Patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations exhibit varying responses to tyrosine kinase inhibitor (TKI) therapy depending on the insertion site of the mutation. Specifically, patients with insertions in the tyrosine kinase domain (TKD) frequently exhibit drug resistance compared to those with insertions in the juxtamembrane domain (JMD). This study aimed to characterize the molecular basis of this resistance and identify new therapeutic strategies to improve outcomes for resistant patients.
The researchers developed a computational strategy named SignalingProfiler to integrate multi-omics datasets—including high-sensitive mass spectrometry-based phosphoproteomics and RNA sequencing—with literature-derived causal signaling networks. By comparing Ba/F3 cell lines expressing FLT3-ITD mutations in either the JMD or TKD regions, the team generated genotype-specific predictive models to map the signaling rewiring induced by TKI treatment.
Large-scale profiling revealed that the different ITD insertion sites primarily impact the cell regulatory network at the post-translational level. The models identified the WEE1-CDK1 axis as a crucial mediator of resistance in TKD-mutated cells. Specifically, TKI treatment in these resistant cells leads to the accumulation of an inactive, stockpiled CDK1-Cyclin B complex, which allows cells to bypass checkpoints and continue the cell cycle. In contrast, sensitive JMD-mutated cells undergo G1 arrest and apoptosis following TKI treatment. Pharmacological inhibition of the WEE1 kinase with adavosertib effectively rewired this signaling, forcing resistant cells into unscheduled mitosis and significantly enhancing the pro-apoptotic effects of TKI therapy in both cell lines and patient-derived primary blasts.
This study provides a mechanistic explanation for why specific FLT3-ITD mutations lead to therapeutic failure. By identifying the WEE1-CDK1 axis as a druggable vulnerability, the authors offer a promising combination therapy strategy to overcome resistance in patients who currently lack effective options. The study also highlights the importance of stratifying patients based on ITD insertion sites to personalize treatment plans.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.